The US Food and Drug Administration (FDA) has approved the humanized monoclonal antibody fremanezumab-vfrm for migraine prevention in adults, the manufacturer has announced. The injectable calcitonin-gene-related peptide (CGRP) antagonist "is the first and only anti-CGRP treatment for the prevention of a migraine with quarterly (675 mg) and monthly (225 mg) dosing options," the company said in a press release. It's now offered as once-monthly 70- or 140-mg single-use prefilled autoinjectors.
"About 40% of people living with a migraine may be appropriate candidates for preventive treatment, yet the majority of them are untreated. I am pleased to have another treatment option that may allow my patients to experience fewer monthly migraine days," Silberstein said. At the 2017 American Headache Society Annual Scientific Meeting, investigators presented detailed results from two phase 3…
